LENZ plans NDA sub­mis­sion for pres­by­opia eye drops this year, looks to launch in 2025

LENZ Ther­a­peu­tics plans to seek FDA ap­proval for its in­ves­ti­ga­tion­al eye drops for pres­by­opia, set­ting up the drug to com­pete against Ab­b­Vie’s Vuity and Ora­sis Phar­ma­ceu­ti­cals’ Qlosi.

The bio­phar­ma on Wednes­day shared pos­i­tive Phase 3 da­ta for two for­mu­la­tions of the treat­ment, say­ing both met the study’s pri­ma­ry end­point, though it plans to pur­sue an NDA for the ver­sion that doesn’t in­clude bri­moni­dine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER